EGFR and neoplasm: Importantly, the functions induced by anti-TGF-β or anti-PD-1 monotherapy were further enhanced by the combination of anti-TGF-β and anti-PD-1 treatments (Fig. 4I, J, Figs. S7H, I, S8H, I, S9H, I), contributing to the significant reduction in EGFR-mutated tumor growth in vivo.